Literature DB >> 24481298

Regulatory watch: Where do new medicines originate from in the EU?

Helene Lincker1, Constantinos Ziogas1, Melanie Carr1, Nuria Porta1, Hans-Georg Eichler1.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24481298     DOI: 10.1038/nrd4232

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

1.  Regulatory watch: Outcomes of EMA marketing authorization applications: does partnering have an influence?

Authors:  Cornelis A van den Bogert; Patrick C Souverein; Michelle Putzeist; Hubert G M Leufkens; Susan W J Janssen; Gerard H Koëter
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

Review 2.  Affordable orphan drugs: a role for not-for-profit organizations.

Authors:  Elin H Davies; Emma Fulton; Daniel Brook; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2017-02-08       Impact factor: 4.335

Review 3.  Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

Authors:  Toon van der Gronde; Carin A Uyl-de Groot; Toine Pieters
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

Review 4.  Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012.

Authors:  Thomas J Hwang; Julie C Lauffenburger; Jessica M Franklin; Aaron S Kesselheim
Journal:  JACC Basic Transl Sci       Date:  2016-08-29

5.  Ideation and implementation of an open science drug discovery business model - M4K Pharma.

Authors:  Maxwell Robert Morgan; Owen Gwilym Roberts; Aled Morgan Edwards
Journal:  Wellcome Open Res       Date:  2018-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.